Sec Form 3 Filing - Hunt Nimrata @ IDEXX LABORATORIES INC /DE - 2020-01-15

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Hunt Nimrata 2. Issuer Name and Ticker or Trading Symbol IDEXX LABORATORIES INC /DE [ IDXX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Executive Vice President (Last) (First) (Middle) IDEXX LABORATORIES, INC., ONE IDEXX DRIVE 3. Date of Earliest Transaction (MM/DD/YY) 01/15/2020 (Street) WESTBROOK, ME04092 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 10,105 D Common Stock 160 I jointly with spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Stock Unit ( 1 ) ( 1 ) ( 1 ) Common Stock 1,957 ( 1 ) D Incentive Stock Option (right-to-buy) $ 79.54 ( 11 ) ( 2 ) 02/13/2025 Common Stock 698 ( 11 ) D Non-Qualified Stock Option (right-to-buy) $ 67.85 ( 3 ) 02/13/2026 Common Stock 27 D Incentive Stock Option (right-to-buy) $ 67.85 ( 4 ) 02/13/2026 Common Stock 1,876 D Non-Qualified Stock Option (right-to-buy) $ 141.6 ( 5 ) 02/13/2027 Common Stock 1,729 D Incentive Stock Option (right-to-buy) $ 141.6 ( 6 ) 02/13/2027 Common Stock 1,043 D Non-Qualified Stock Option (right-to-buy) $ 178.26 ( 7 ) 02/13/2028 Common Stock 5,865 D Incentive Stock Option (right-to-buy) $ 178.26 ( 8 ) 02/13/2028 Common Stock 560 D Non-Qualified Stock Option (right-to-buy) $ 206.94 ( 9 ) 02/13/2029 Common Stock 5,711 D Incentive Stock Option (right-to-buy) $ 206.94 ( 10 ) 02/13/2029 Common Stock 483 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Hunt Nimrata IDEXX LABORATORIES, INC. ONE IDEXX DRIVE WESTBROOK, ME04092 Executive Vice President Signatures /s/ Lily J. Lu, Attorney-in-Fact for Nimrata Hunt 01/24/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split"). ( 2 )Grant of option to buy 1,366 shares of Issuer common stock that vest in five annual installments beginning on February 14, 2016, without giving effect to the Stock Split. ( 3 )Grant of option to buy 1,940 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2017. ( 4 )Grant of option to buy 1,906 shares of Issuer common stock that vests as to 30 shares on February 14, 2018, 365 shares on February 14, 2020, and as to the remainder on February 14, 2021. ( 5 )Grant of option to buy 3,579 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2018. ( 6 )Grant of option to buy 1,043 shares of Issuer common stock that vests in one installment on February 14, 2022. ( 7 )Grant of option to buy 5,685 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2019. ( 8 )Grant of option to buy 560 shares of Issuer common stock that vests in one installment on February 14, 2023. ( 9 )Grant of option to buy 5,711 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2020. ( 10 )Grant of option to buy 483 shares of Issuer common stock that vests in one installment on February 14, 2024. ( 11 )The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.